Clinical studies have shown high levels of Sigmar1 in tumor tissues from breast cancer patients and has been proposed to be used as a clinical marker of breast cancer (Simony-Lafontaine et al., 2000). This evidence concerns the gene SIGMAR1 and breast cancer.